Results 241 to 250 of about 34,445,663 (284)

Association between glucagon-like peptide-1 receptor agonist use and peri-operative pulmonary aspiration: a systematic review and meta-analysis

Anaesthesia
INTRODUCTION: Glucagon-like peptide-1 receptor agonists are known to delay gastric emptying; however, the association between glucagon-like peptide-1 receptor agonist use and peri-operative pulmonary aspiration risk is not known.
Tim Spelman, Cade Shadbolt, Peter Choong
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists

JAMA
This Viewpoint discusses the health benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs); summarizes the clinical, policy, and equity implications of GLP-1 RA discontinuation; and calls for the identification and implementation of strategies to improve long-term adherence to GLP-1 RA therapy.
Sadiya S, Khan, Chiadi E, Ndumele, Dhruv S, Kazi   +2 more
openaire   +2 more sources

Obesity and Glucagon-Like Peptide-1 Receptor Agonists

JAMA
This Viewpoint discusses factors associated with the prevalence of obesity worldwide and whether the novel glucagon-like peptide-1 receptor agonists (GLP-1) can help unlock a health systems response to the obesity pandemic.
Francesca, Celletti, Francesco, Branca, Jeremy, Farrar   +2 more
openaire   +2 more sources

Glucagon-Like Peptide 1 Receptor Agonists in Psychiatry

Journal of Clinical Psychopharmacology
The glucagon-like peptide 1 (GLP-1)–based diabetes and obesity drug semaglutide, with trade names Ozempic and Wegovy, will become the second best-selling drug in 2024, with estimated worldwide Ozempic sales of US ~$16 billion. Finally, the pharmacological treatment of obesity seems to have a breakthrough after decades of setbacks, with previous weight ...
Himmerich, Hubertus, McElroy, Susan L
openaire   +3 more sources

Glucagon-like peptide-1 receptor agonists and the eye

Current Opinion in Ophthalmology
Purpose of review Glucagon-like peptide-1 receptor agonists (GLP-1RA) have gained popularity as an antidiabetic and weight loss agent with protective cardiovascular outcomes, but attention to the potential ocular side effects has grown.
David L, Zhang, Avni P, Finn
openaire   +2 more sources

Cardioprotective Effects of Glucagon-Like Peptide 1 Receptor Agonists

Kardiologiia, 2014
In this paper we discuss pathogenetic mechanisms of cardiovascular risk reduction in patients with type 2 diabetes mellitus by glucagon-like peptide 1 (GLP-1) receptor agonists. Results of experimental studies and randomized clinical studies are presented, and perspectives for using GLP-1 agonists in patients with diabetic cardiovascular complications ...
A S, Ametov, L L, Kamynina, Z G, Akhmedova   +2 more
openaire   +2 more sources

Renal protection with glucagon-like peptide-1 receptor agonists

Current Opinion in Pharmacology, 2020
There is an unmet need for renoprotective drugs for more pronounced reduction of albuminuria beyond that provided by renin-angiotensin system (RAS) blockers and for effective slowdown of eGFR decline independent of albuminuria. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have proven effective in reducing prespecified secondary composite ...
Vitale M., Haxhi J., Cirrito T., Pugliese G.   +3 more
openaire   +2 more sources

Glucagon-like peptide-1 receptor agonists in rheumatoid arthritis

Current Opinion in Rheumatology
Purpose of review This article synthesizes current preclinical and clinical literature regarding glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in rheumatoid arthritis (RA), highlights mechanistic hypotheses and explores potential clinical roles and limitations of their use.
Ryan, Massay, Angela, Malani, Aaron, Stubbs   +2 more
openaire   +2 more sources

The Discovery and Development of Glucagon-Like Peptide-1 Receptor Agonists

Current Medicinal Chemistry
Abstract: Diabetes mellitus has become a serious life-threatening disease. As one of the new drugs for the treatment of diabetes, GLP-1 receptor agonists have attracted a lot of attention. Compared with traditional hypoglycemic drugs, GLP-1 receptor agonists have good safety and tolerability. To a certain extent, they overcome the problem of the short
Haowen, Fang, Bing, Niu, Qin, Chen
openaire   +2 more sources

[Glucagon-like peptide-1 receptor agonists].

Nihon rinsho. Japanese journal of clinical medicine, 2015
Recently, the number of diabetic patients with obesity has increased by changes in life-style including food and physical exercise. Appearance of incretin-related drugs has given us more options for treating type 2 diabetes, and they are evaluated in regard to realizing appropriately controlled glycemic status.
Yamato, Mashimo, Kazuhiro, Eto
openaire   +1 more source